SpineVision

The company's business model centers on in-house research and development, conducted in collaboration with orthopedic and neurosurgeons, while outsourcing production. This approach has led to a portfolio of over 20 patents. SpineVision generates revenue by selling its comprehensive suite of spinal treatment products to its primary clients: orthopedic surgeons and neurosurgeons. The company's strategy initially focused on creating a complete line of spinal products to compete with market leaders. More recently, it has emphasized a combination of dynamic stabilization and minimally invasive surgery. The firm has raised a total of $36.1 million over four funding rounds, with the latest being a Series B round in 2013.

A key product is the Hexanium TLIF cage, a titanium 3D-printed implant for spine fusion surgery that has received both FDA clearance and CE Mark approval. This product features a honeycomb-like structure and a roughened titanium surface to promote rapid osseointegration and reduce the risk of post-operative subsidence. Other notable products include the Flex+2 dynamic stabilization system and the LUMIS minimally invasive system. The company leverages 3D printing not only for prototyping, which accelerates development and improves communication with surgeons, but also for producing small series of titanium parts on demand, optimizing the supply chain. The current CEO is Arnaud Brisard, who brings over 20 years of experience from technology and defense sectors at companies like Alcatel and Netasq before joining SpineVision.